Citigroup’s Aegerion Pharmaceuticals AEGR Stock Holding History

Citigroup’s Portfolio AEGR Stock Details AEGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-3,000	Closed	-$9K	–	7476
2016 Q3	$9K	Sell	3,000 -4,600	-61%	-$7.97K	﹤0.01%	6607
2016 Q2	$11K	Buy	7,600 +1,900	+33%	+$4.35K	﹤0.01%	6529
2016 Q1	$21K	Sell	5,700 -14,200	-71%	-$87.9K	﹤0.01%	6534
2015 Q4	$201K	Buy	19,900 +16,400	+469%	+$197K	﹤0.01%	4743
2015 Q3	$48K	Buy	3,500 +2,000	+133%	+$35.6K	﹤0.01%	5469
2015 Q2	$28K	Buy	+1,500	New	+$32.5K	﹤0.01%	5916

Citigroup's AEGR Position: Q4 2016 in Review

Citigroup sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2016, closing a stake of 58,529 shares — an estimated $174K sold.

Citigroup first reported a position in AEGR in Q2 2013 and held it in 14 quarters. The position peaked at $1.14M in Q4 2013. 0 funds tracked by Wall St. Rank hold AEGR as of Q4 2016.

Citigroup reported no remaining Aegerion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Citigroup sold 58,529 Aegerion Pharmaceuticals shares in Q4 2016, an estimated $174K.
Citigroup first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 14 quarters.
Citigroup's Aegerion Pharmaceuticals position peaked at $1.14M in Q4 2013.
0 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2016.

Based on Citigroup's 13F filing for Q4 2016, filed 10 Feb 2017.